Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
about
The influence of subclonal resistance mutations on targeted cancer therapyCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaImpact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trialOutcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyAllogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adultsImatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice.Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia.Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimenA review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.Novel targeted drug therapies for the treatment of childhood acute leukemiaPhiladelphia chromosome-positive acute lymphoblastic leukemia.Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients.Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia.Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options.Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives.Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly.Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult.Tyrosine kinase inhibitors in acute and chronic leukemias.Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy.Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission.Current and future management of Ph/BCR-ABL positive ALL.Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.Advances in adult acute lymphoblastic leukemia therapy.Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy.Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China.Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.Morphologic detection of blast cells in the cerebrospinal fluid at diagnosis of adult acute lymphoblastic leukemia appears to be associated with adverse prognosis.Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
P2860
Q26781693-669C62ED-EAA8-41C0-AEED-F3F424673C10Q27025242-22DBD74B-780C-44A0-947B-5464DF07822FQ33304051-A1EF4736-5716-48D9-9912-0A81CBB5CF10Q33587563-FBC717CD-F10C-45F0-9780-1E011A35062EQ33800438-A5A20410-E36D-44CE-AA8F-C8F60C780E32Q33915980-4515BAD4-CA1D-4893-88FB-32F502BB0F80Q34557165-727E4E6E-17B3-459D-8349-7B746AAD2C6EQ35146312-BAB3ACDA-4725-401B-806A-DF700674CFE8Q36201257-898B018F-8D83-435F-87B2-F450960A54C4Q36461915-4B5FE901-064A-45E5-B11C-36C40AE33A7BQ36634604-998D1552-F0D0-4D5D-9D0D-246BA8FFE91EQ36758604-D5B9D018-DE58-4506-9F9E-C98EE960226CQ36787572-C3FCFE1D-3905-4AA1-AED5-AC03BFC26775Q36979320-273D6DD6-5B22-44AA-84D8-32F2CA13378FQ37477482-52C83111-27D8-4A4C-AC4F-B6CFB031DCF1Q37613888-F3D980A3-33DC-49E4-94A2-FF6AB50AC296Q37630453-2F7727D2-3B90-437B-BDE5-4236587FF2DEQ37650203-F3278416-23F0-4A00-9773-F835801C3502Q37810095-3EECB115-2A40-4A65-9CAB-005449BA3EA5Q37810967-455E058B-DBB7-4F0E-BEB5-13F8B9300B24Q37862648-3DE425CA-E9F0-4429-991A-F77613009744Q37875969-5FA57AF1-11A2-4A07-91EC-BCB994426EA8Q37931235-F928923D-4AFE-41F0-AAEE-333CCAC4B23FQ37947940-AA990F50-0578-4A1B-AB48-8AD3EA4BD538Q38004075-D3C31B84-94D0-4528-BBFC-5A806262F826Q38044901-32EC807A-C5BA-4D22-9883-C02B836091E7Q38079288-06EB9DB9-3FB4-414D-B36E-8E2E3A984F77Q38194585-547520F6-C77E-4543-BA07-4A61DC947518Q38207017-F366352A-CCD0-4A1E-99EC-43F1FB25DCD4Q38423781-9A51B5C0-9633-4FE4-900F-DDCFE3344FF8Q38734309-BC396DAF-5E63-4447-962B-FF5A470A87AFQ38739574-A1A99E46-37BC-4B5C-8F22-0F1B501C4928Q39112294-1A38B000-1735-461A-9217-D1A4B4816DC5Q39459190-59D96F2D-0867-4238-A120-8FFFFF1DEB82Q39657505-B227805D-2261-446A-88D8-76404872F47EQ41534360-7D4B598F-146C-442B-92AD-0ED046F635DBQ43168908-8D23FE3F-0A05-430B-8ED1-898E6DCBA937Q43175147-0B50C763-864A-4B81-84A7-EDA6480FC6A3Q43666664-151B0D5A-D7C9-4348-B1CE-B6D05EFCD2ECQ46341511-86359F2D-ADDF-470A-93E6-F2AF75682CF6
P2860
Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Clinical effect of imatinib ad ...... acute lymphoblastic leukemia.
@en
Clinical effect of imatinib ad ...... acute lymphoblastic leukemia.
@nl
type
label
Clinical effect of imatinib ad ...... acute lymphoblastic leukemia.
@en
Clinical effect of imatinib ad ...... acute lymphoblastic leukemia.
@nl
prefLabel
Clinical effect of imatinib ad ...... acute lymphoblastic leukemia.
@en
Clinical effect of imatinib ad ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P356
P1433
P1476
Clinical effect of imatinib ad ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403886
P577
2005-09-01T00:00:00Z